Arcus Biosciences Inc (NYSE:RCUS)
$ 15.07 0.14 (0.94%) Market Cap: 1.37 Bil Enterprise Value: 373.93 Mil PE Ratio: 0 PB Ratio: 1.94 GF Score: 73/100

Arcus Biosciences Inc Corporate Update Transcript

May 27, 2020 / 12:00PM GMT
Release Date Price: $27.05 (-19.35%)
Operator

Good morning. My name is Carol, and I will be your conference operator today. At this time, I would like to welcome everyone to the Arcus Biosciences Corporate Update Conference Call. (Operator Instructions)

I will now hand the call off to Katie Bock, Vice President of Investor Relations and Corporate Strategy at Arcus. Katie, you may begin your conference.

Katherine Bock
Arcus Biosciences, Inc. - VP of IR & Corporate Strategy

Hi, everyone. Thank you, Carol. Thank you all for participating in today's call on such short notice. Today, we will be discussing this morning's announcement regarding Arcus-Gilead partnership. Joining me from Arcus are Terry Rosen, Chief Executive Officer; Juan Jaen, President; and Bill Grossman, Chief Medical Officer.

I'd like to remind you that on this call, management will make forward-looking statements within the meaning of securities law safe harbor provisions, for example, statements about the payments and other benefits we anticipate receiving under the Arcus-Gilead partnership. All statements other than

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot